Artera, a leader in multimodal artificial intelligence (MMAI)-based cancer diagnostics, has announced the presentation of three groundbreaking abstracts at the San Antonio Breast Cancer Symposium (SABCS) 2025, showcasing the clinical utility of its AI platform in breast cancer risk stratification and chemotherapy prediction. The studies represent the first multi-country validation of an AI model across more than 7,000 patients from four independent Phase III trials in Germany, Austria, and North America. The research demonstrates that Artera’s MMAI model can accurately predict the risk of distant metastasis and identify which patients are most likely to benefit from chemotherapy, particularly in postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer. This capability supports more personalized treatment decisions, helping clinicians avoid unnecessary chemotherapy and its associated toxicities. Professor Nadia Harbeck, Director of the Breast Center at LMU University Hospital in Munich, Germany, emphasized the significance of the findings. She noted that traditional methods often lead to postmenopausal, node-negative patients receiving chemotherapy with minimal benefit, exposing them to serious side effects such as neuropathy, infection risk, and fertility issues. She welcomed the emergence of AI-driven tools that enable more precise, individualized care. Andre Esteva, CEO of Artera, highlighted the broader impact of the technology. He stated that advancing precision medicine means delivering tailored care that is both effective and accessible. The validation of the MMAI model across diverse populations and clinical settings underscores its potential to improve outcomes while reducing unnecessary treatments without adding complexity or cost. Key presentations include: Poster Spotlight 11 (PD11-01) – The development of Artera’s MMAI model using data from over 12,000 patients across six Phase III trials in the U.S., Germany, and Austria. The model effectively stratified patients by 10-year risk of distant metastasis, identifying high-risk individuals who may need closer monitoring. Notably, 68% of patients were classified as low-risk, with an estimated 10-year disease-free survival rate of nearly 95%. Poster Session 3 (PS3-04-08) – Independent validation of the MMAI biomarker in the ABCSG Trial 8, which included postmenopausal patients receiving endocrine therapy only. The model successfully categorized patients into low, intermediate, and high-risk groups with corresponding 10-year disease-free survival rates of approximately 95%, 89%, and 77%. The results were consistent across key clinical subgroups, including tumor grade, lymph node status, and proliferation markers. The test is non-invasive and offers rapid turnaround, providing a cost-effective alternative to genomic assays. Rapid Fire 3 (RF3-03) – Evaluation of the MMAI model in the NSABP B-20 trial, focusing on node-negative, HR+ patients aged 50 and older. High-risk patients identified by MMAI experienced a 52% relative reduction in distant metastasis with chemotherapy, while low-risk patients showed no additional benefit. This finding supports the model’s ability to guide treatment decisions by identifying those who truly need chemotherapy. Artera will be exhibiting at booth #1525 during SABCS, where attendees can explore the MMAI platform and the ArteraAI Breast Test. Headquartered in Los Altos, California, Artera operates a CLIA-certified clinical laboratory in Jacksonville, Florida. The company’s MMAI-powered tests are available in multiple regions, including the ArteraAI Breast Test (UKCA), ArteraAI Prostate Test (FDA and UKCA), and ArteraAI Prostate Biopsy Assay (UKCA). Artera continues to expand its global footprint in precision oncology through validated, AI-driven solutions. For more information, visit artera.ai.